Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neoadjuvant Phase II Trial Combining [3 FEC 100 Followed by 3 Docetaxel Associated With Trastuzumab Plus Pertuzumab] or [6 Docetaxel, Carboplatin Associated With Trastuzumab Plus Pertuzumab] According to TOP2A Status in Patients With T1c Operable, HER2-positive Breast Cancer

Next Previous
Trial Profile

Neoadjuvant Phase II Trial Combining [3 FEC 100 Followed by 3 Docetaxel Associated With Trastuzumab Plus Pertuzumab] or [6 Docetaxel, Carboplatin Associated With Trastuzumab Plus Pertuzumab] According to TOP2A Status in Patients With T1c Operable, HER2-positive Breast Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Cyclophosphamide (Primary) ; Docetaxel (Primary) ; Epirubicin (Primary) ; Fluorouracil (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
  • Indications Early breast cancer; HER2 positive breast cancer
  • Focus Therapeutic Use
  • Acronyms GEP13-NEOTOP; NeoTOP
  • Sponsors UNICANCER

Most Recent Events

  • 08 Nov 2024 Status changed from active, no longer recruiting to completed.
  • 01 Jun 2024 Results assessing the complementary action of Trastuzumab and Pertuzumab, and the relevance of an anthracycline-based regimen according to TOP2A amplification status, published in the Breast Cancer Research and Treatment
  • 06 Dec 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top